0001179110-11-008678.txt : 20110526
0001179110-11-008678.hdr.sgml : 20110526
20110526170629
ACCESSION NUMBER: 0001179110-11-008678
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20110525
FILED AS OF DATE: 20110526
DATE AS OF CHANGE: 20110526
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: WEISER MICHAEL
CENTRAL INDEX KEY: 0001221449
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33038
FILM NUMBER: 11875078
MAIL ADDRESS:
STREET 1: 130 EAST 75TH ST
STREET 2: APT 6B
CITY: NEW YORK
STATE: NY
ZIP: 10021
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ZIOPHARM ONCOLOGY INC
CENTRAL INDEX KEY: 0001107421
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-SPECIALTY OUTPATIENT FACILITIES, NEC [8093]
IRS NUMBER: 841475642
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1180 AVENUE OF THE AMERICA
STREET 2: 19TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10036
BUSINESS PHONE: 646-214-0700
MAIL ADDRESS:
STREET 1: 1180 AVENUE OF THE AMERICA
STREET 2: 19TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10036
FORMER COMPANY:
FORMER CONFORMED NAME: EASYWEB INC
DATE OF NAME CHANGE: 20010213
4
1
edgar.xml
FORM 4 -
X0303
4
2011-05-25
0
0001107421
ZIOPHARM ONCOLOGY INC
ZIOP
0001221449
WEISER MICHAEL
C/O ZIOPHARM ONCOLOGY, INC.
1180 AVENUE OF THE AMERICAS, SUITE 1920
NEW YORK
NY
10036
1
0
0
0
Common Stock, $.001 par value
2011-05-25
4
S
0
15000
6.53
D
135945
D
Warrants to Purchase Common Stock
4.75
2005-09-13
2012-05-31
Common Stock, $.001 par value
35566
35566
D
Director Stock Option (right to buy)
4.31
2007-07-20
2014-12-22
Common Stock, $.001 par value
15029
15029
D
Director Stock Option (right to buy)
5.01
2006-04-26
2016-04-26
Common Stock, $.001 par value
15000
15000
D
Warrants to purchase Common Stock
5.09
2006-05-03
2013-05-03
Common Stock, $.001 par value
18319
18319
D
Director Stock Option (right to buy)
6.49
2009-12-13
2016-12-13
Common Stock, $.001 par value
15000
15000
D
Stock Option (right to buy)
4.85
2010-06-18
2017-06-18
Common Stock
15000
15000
D
Stock Option (right to buy)
2.73
2017-12-12
Common Stock
20000
20000
D
Stock Option (right to buy)
0.70
2019-05-13
Common Stock
15000
15000
D
Stock Options (right to buy)
2.85
2019-12-31
Common Stock, $.001 par value
7500
7500
D
Stock Options (right to buy)
5.09
2011-03-31
2020-03-31
Common Stock, $.001 par value
15000
15000
D
Stock Option (right to buy)
4.77
2020-12-31
Common Stock
30000
30000
D
Proceeds from the sales reported on this form were used to offset the reporting person's payment of tax obligations triggered by the vesting of previously awarded restricted stock. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.51 to $6.57, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth.
Includes grants of restricted stock with restrictions that lapsed as to 3,750 shares on December 31, 2010 and as to 15,000 shares on March 31, 2011; and restrictions that will lapse as to 3,750 shares on December 31, 2011.
6,667 shares vest on each of 12/12/08 and 12/12/09; 6,666 shares vest on 12/12/10.
5,000 shares vest on each of 12/31/09, 6/30/2010 and 12/31/2010.
3,750 shares vest on each of 12/31/2010 and 12/31/2011.
10,000 shares vest on each of 12/31/2011, 12/31/2012 and 12/31/2013.
Exhibit 24.1 Power of Attorney attached.
/s/ Richard E. Bagley as attorney-in-fact for Michael Weiser
2011-05-26
EX-24.1
2
exhibit24.txt
POWER OF ATTORNEY
POWER OF ATTORNEY
For Executing Forms 3, 4 and 5
Know all by these presents, that the undersigned hereby
constitutes and appoints Jonathan Lewis and Richard E.
Bagley, signing individually, his true and lawful attorneys-
in-fact to:
1. Execute for and on behalf of the undersigned Initial
Statements of Beneficial Ownership of Securities on Form 3,
Statements of Changes of Beneficial Ownership of Securities
on Form 4 and Annual Statements of Beneficial Ownership of
Securities on Form 5, for the purpose of reporting
transactions by the undersigned in securities issued by
Ziopharm Oncology, Inc. in accordance with Section 16(a) of
the Securities Exchange Act of 1934 and the rules
thereunder;
2. Do and perform any and all acts for and on behalf of
the undersigned which may be necessary or desirable to
complete the execution of any such Form 3, 4 or 5 and the
timely filing thereof with the United States Securities and
Exchange Commission and any other applicable governmental or
regulatory authority; and
3. Take any other action of any type whatsoever in
connection with the foregoing which in the opinion of such
attorney-in-fact, may be of benefit to, in the best interest
of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney-in-
fact on behalf of the undersigned pursuant to this Power of
Attorney shall be in such form and shall contain such terms
and conditions as such attorney-in-fact may approve in his
discretion.
The undersigned hereby grants to each such attorney-in-fact
full power and authority to do and perform all and every act
and thing whatsoever requisite, necessary and proper to be
done in the exercise of any of the rights and powers herein
granted, as fully to all intents and purposes as such
attorney-in-fact might or could do if personally
present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-
in-fact, or his substitute or substitutes, shall lawfully
do or cause to be done by virtue of this power of attorney
and the rights and powers herein granted. The undersigned
acknowledges that the foregoing attorneys-in-fact, in
serving in such capacity at the request of the
undersigned, are not assuming any of the undersigned's
responsibilities to comply with Section 16 of the
Securities Exchange Act of 1934.
This Power of Attorney shall remain in full force and effect
until the undersigned is no longer required to file Forms 3,
4 and 5 with respect to the undersigned's holdings of and
transactions in securities issued by Ziopharm Oncology,
Inc., unless earlier revoked by the undersigned in a
signed writing delivered to the foregoing attorneys-in-fact.
IN WITNESS WHEREOF, the undersigned has executed this Power
of Attorney as of this 24 day of June, 2009.
/s/ Michael Weiser
(signature)
_Michael Weiser _